A Virtual Reality-Based App to Educate Health Care Professionals and Medical Students About Inflammatory Arthritis: Feasibility Study.

feasibility inflammatory arthritis psoriatic arthritis rheumatoid arthritis virtual reality

Journal

JMIR serious games
ISSN: 2291-9279
Titre abrégé: JMIR Serious Games
Pays: Canada
ID NLM: 101645255

Informations de publication

Date de publication:
11 May 2021
Historique:
received: 27 08 2020
accepted: 13 03 2021
revised: 23 11 2020
entrez: 11 5 2021
pubmed: 12 5 2021
medline: 12 5 2021
Statut: epublish

Résumé

Inflammatory arthritides (IA) such as rheumatoid arthritis or psoriatic arthritis are disorders that can be difficult to comprehend for health professionals and students in terms of the heterogeneity of clinical symptoms and pathologies. New didactic approaches using innovative technologies such as virtual reality (VR) apps could be helpful to demonstrate disease manifestations as well as joint pathologies in a more comprehensive manner. However, the potential of using a VR education concept in IA has not yet been evaluated. We evaluated the feasibility of a VR app to educate health care professionals and medical students about IA. We developed a VR app using data from IA patients as well as 2D and 3D-visualized pathological joints from X-ray and computed tomography-generated images. This VR app (Rheumality) allows the user to interact with representative arthritic joint and bone pathologies of patients with IA. In a consensus meeting, an online questionnaire was designed to collect basic demographic data (age, sex); profession of the participants; and their feedback on the general impression, knowledge gain, and potential areas of application of the VR app. The VR app was subsequently tested and evaluated by health care professionals (physicians, researchers, and other professionals) and medical students at predefined events (two annual rheumatology conferences and academic teaching seminars at two sites in Germany). To explore associations between categorical variables, the χ A total of 125 individuals participated in this study. Among them, 56% of the participants identified as female, 43% identified as male, and 1% identified as nonbinary; 59% of the participants were 18-30 years of age, 18% were 31-40 years old, 10% were 41-50 years old, 8% were 51-60 years old, and 5% were 61-70 years old. The participants (N=125) rated the VR app as excellent, with a mean rating of 9.0 (SD 1.2) out of 10, and many participants would recommend use of the app, with a mean recommendation score of 3.2 (SD 1.1) out of 4. A large majority (120/125, 96.0%) stated that the presentation of pathological bone formation improves understanding of the disease. We did not find any association between participant characteristics and evaluation of the VR experience or recommendation scores. The data show that IA-targeting innovative teaching approaches based on VR technology are feasible.

Sections du résumé

BACKGROUND BACKGROUND
Inflammatory arthritides (IA) such as rheumatoid arthritis or psoriatic arthritis are disorders that can be difficult to comprehend for health professionals and students in terms of the heterogeneity of clinical symptoms and pathologies. New didactic approaches using innovative technologies such as virtual reality (VR) apps could be helpful to demonstrate disease manifestations as well as joint pathologies in a more comprehensive manner. However, the potential of using a VR education concept in IA has not yet been evaluated.
OBJECTIVE OBJECTIVE
We evaluated the feasibility of a VR app to educate health care professionals and medical students about IA.
METHODS METHODS
We developed a VR app using data from IA patients as well as 2D and 3D-visualized pathological joints from X-ray and computed tomography-generated images. This VR app (Rheumality) allows the user to interact with representative arthritic joint and bone pathologies of patients with IA. In a consensus meeting, an online questionnaire was designed to collect basic demographic data (age, sex); profession of the participants; and their feedback on the general impression, knowledge gain, and potential areas of application of the VR app. The VR app was subsequently tested and evaluated by health care professionals (physicians, researchers, and other professionals) and medical students at predefined events (two annual rheumatology conferences and academic teaching seminars at two sites in Germany). To explore associations between categorical variables, the χ
RESULTS RESULTS
A total of 125 individuals participated in this study. Among them, 56% of the participants identified as female, 43% identified as male, and 1% identified as nonbinary; 59% of the participants were 18-30 years of age, 18% were 31-40 years old, 10% were 41-50 years old, 8% were 51-60 years old, and 5% were 61-70 years old. The participants (N=125) rated the VR app as excellent, with a mean rating of 9.0 (SD 1.2) out of 10, and many participants would recommend use of the app, with a mean recommendation score of 3.2 (SD 1.1) out of 4. A large majority (120/125, 96.0%) stated that the presentation of pathological bone formation improves understanding of the disease. We did not find any association between participant characteristics and evaluation of the VR experience or recommendation scores.
CONCLUSIONS CONCLUSIONS
The data show that IA-targeting innovative teaching approaches based on VR technology are feasible.

Identifiants

pubmed: 33973858
pii: v9i2e23835
doi: 10.2196/23835
pmc: PMC8150404
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e23835

Informations de copyright

©Philipp Klemm, Arnd Kleyer, Koray Tascilar, Louis Schuster, Timo Meinderink, Florian Steiger, Uwe Lange, Ulf Müller-Ladner, Johannes Knitza, Philipp Sewerin, Johanna Mucke, Axel J Hueber, Georg Schett, Fabian Hartmann, Axel J Hueber, David Simon. Originally published in JMIR Serious Games (https://games.jmir.org), 11.05.2021.

Références

AJR Am J Roentgenol. 2020 Jan;214(1):W55-W61
pubmed: 31691611
Arthritis Rheumatol. 2020 Feb 18;:
pubmed: 32067367
Bone. 2018 Nov;116:87-93
pubmed: 30048820
N Engl J Med. 2011 Dec 8;365(23):2205-19
pubmed: 22150039
J Bone Miner Res. 2017 Apr;32(4):722-730
pubmed: 27787923
Ann Rheum Dis. 2015 Jan;74(1):8-13
pubmed: 25261577
RMD Open. 2016 Jul 27;2(2):e000240
pubmed: 27493789
Arthritis Rheum. 1983 Nov;26(11):1346-53
pubmed: 6639693
JMIR Ment Health. 2016 Jun 27;3(2):e28
pubmed: 27349654
J Bone Miner Res. 2020 Sep;35(9):1695-1702
pubmed: 32395822
JMIR Ment Health. 2019 Jan 31;6(1):e11973
pubmed: 30702436
ACR Open Rheumatol. 2019 Nov 11;1(10):667-675
pubmed: 31872189
Arthritis Res Ther. 2020 Jan 2;22(1):1
pubmed: 31898524
Z Rheumatol. 2019 Mar;78(2):112-115
pubmed: 30694358
Cyberpsychol Behav Soc Netw. 2013 Mar;16(3):215-23
pubmed: 23496678
JMIR Mhealth Uhealth. 2019 Aug 05;7(8):e14991
pubmed: 31381501
Arthritis Care Res (Hoboken). 2019 Oct;71(10):1336-1343
pubmed: 30242992
J Gerontol B Psychol Sci Soc Sci. 1998 Sep;53(5):P329-40
pubmed: 9750571
Int J Rheum Dis. 2019 Jan;22(1):55-61
pubmed: 28205411
Hum Factors. 1999 Sep;41(3):345-55
pubmed: 10665203
Ann Rheum Dis. 2018 Jul;77(7):973-980
pubmed: 29475856
Insights Imaging. 2013 Dec;4(6):799-810
pubmed: 24127271
Arthritis Res Ther. 2018 Aug 31;20(1):203
pubmed: 30170626
N Engl J Med. 2017 Mar 9;376(10):957-970
pubmed: 28273019
Ann Rheum Dis. 2017 May;76(5):882-885
pubmed: 28093419
Z Rheumatol. 2019 Oct;78(8):692-697
pubmed: 31468164
Anat Sci Educ. 2019 May;12(3):257-263
pubmed: 30395696
Psychol Aging. 2006 Jun;21(2):333-52
pubmed: 16768579
RMD Open. 2019 Jun 25;5(2):e000950
pubmed: 31321076

Auteurs

Philipp Klemm (P)

Department of Rheumatology, Immunology, Osteology and Physical Medicine, Justus-Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany.

Arnd Kleyer (A)

Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.

Koray Tascilar (K)

Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.

Louis Schuster (L)

Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.

Timo Meinderink (T)

Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.

Florian Steiger (F)

Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.

Uwe Lange (U)

Department of Rheumatology, Immunology, Osteology and Physical Medicine, Justus-Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany.

Ulf Müller-Ladner (U)

Department of Rheumatology, Immunology, Osteology and Physical Medicine, Justus-Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany.

Johannes Knitza (J)

Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.

Philipp Sewerin (P)

Department and Hiller Research Unit for Rheumatology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

Johanna Mucke (J)

Department and Hiller Research Unit for Rheumatology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

Alexander Pfeil (A)

Department of Internal Medicine 3, Jena University Hospital, Friedrich Schiller University, Jena, Germany.

Georg Schett (G)

Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.

Fabian Hartmann (F)

Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.

Axel J Hueber (AJ)

Sektion Rheumatologie, Sozialstiftung Bamberg, Bamberg, Germany.

David Simon (D)

Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Deutsches Zentrum Immuntherapie, Friedrich-Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.

Classifications MeSH